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Lower urinary tract symptoms
Abstract
Background: Radiation-induced cystitis is a common side effect of radiotherapy
(RT) to the pelvic area. Hyaluronic acid (HA) and chondroitin sulfate (CS) are
components of the urothelial mucosa and positive results have been obtained for
intravesical HA/CS instillations for the treatment of urinary tract infections and
bladder pain syndrome. HA/CS may also have a protective effect against RT bladder
toxicity.
Objective: To investigate whether HA and CS protect the urothelium during RT,
alleviate lower urinary tract symptoms, and improve quality of life.
Design, setting, and participants: This multicentre randomised controlled trial was
conducted across seven centres in four countries. Male patients aged 18 yr
scheduled to undergo primary intensity-modulated radiotherapy for localised
prostate cancer were enrolled.
Intervention: Patients were randomised to intravesical HA/CS plus an oral formu-
lation of curcumin, quercetin, HA, and CS (group A) or no treatment (group B).
Outcome measurements and statistical analysis: The primary endpoint was abso-
lute changes from baseline to follow-up in urinary domain scores for the Expanded
Prostate Cancer Index Composite (EPIC), the International Consultation on Incon-
tinence Questionnaire-Male Lower Urinary Tract Symptoms (ICIQ-MLUTS), and the
EuroQol Group EQ-5D-5L questionnaire. Data analysis for efficacy and safety out-
comes was performed using an intention-to-treat (ITT) approach; the ITT popula-
tion was defined as all randomised patients.. Department of Urology, Humanitas Clinical and Research Center, IRCCS
spital, via Manzoni 56, 20089 Rozzano MI, Italy. Tel. +39 028224 4553;
o.lazzeri@humanitas.it (M. Lazzeri).* Corresponding author
Humanitas Research Ho
Fax: +39 02 8224 8224.
E-mail address: massimhttp://dx.doi.org/10.1016/j.euros.2021.01.016
2666-1683/© 2021 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Results and limitations: Of 57 patients screened, 49 were enrolled and randomly
assigned to either active treatment (group A, n = 25) or the control (group B, n = 24).
Three patients in the control group withdrew after randomisation. Changes from
baseline to 12 mo were worse in the control group for subtotal scores for urinary
symptoms and impact of symptoms on quality of life and for the total score
(p = 0.05, p = 0.003, and p = 0.008, respectively). There was a significant time 
group interaction in favour of active treatment for the incontinence symptom score
(p = 0.011) and bother score (p = 0.017). The absence of a sham procedure and/or
placebo is the main limitation.
Conclusions: Our results suggest that intravesical HA/CS in combination with an
oral formulation may reduce urinary symptoms and improve QoL at short-term
(1 yr) follow-up.
Patient summary: We investigated whether hyaluronic acid (HA) and chondroitin
sulfate (CS) have a protective effect against the bladder toxicity of radiotherapy for
prostate cancer. HA/CS used for weekly bladder irrigation for 6 wk and given orally
with curcumin and quercetin for 12 wk reduced urinary incontinence symptoms
and bother measured at 1-year follow-up. This may hold promise as a preventive
treatment if the results are confirmed in further trials.
© 2021 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creati-
vecommons.org/licenses/by-nc-nd/4.0/).
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Acute and late radiation-induced cystitis is a common side
effect occurring in up to 25% of patients during and after
pelvic organ cancer treatment with radiotherapy (RT)
[1]. Radiation-induced bladder toxicity is characterised by
early acute inflammation, sometimes haemorrhagic, that
resolves in many patients, and late fibrosis with filling/
voiding dysfunction that can occur months or years later.
The acute and late clinical complaints of patients often
resemble those for acute or chronic cystitis, such as bladder
pain syndrome, and some patients may also experience
gross haematuria, which further impacts quality of life
(QoL) and may require invasive treatment [1–3].
Ionising radiation impacts cells, tissues, and pelvic
organs of the body via different mechanisms and effects.
In in vivo animal models, irradiated bladders exhibit
oedema, inflammatory cell infiltrate, blood vessel dilation
and urothelial loss, and exhibit fibrosis and disruption of the
urothelial barrier [4]. The urothelial barrier consists of a
protective mucin layer that contains negatively charged
glycosaminoglycans, the main components of which are
hyaluronic acid (HA) and chondroitin sulfate (CS) [5]. RT
may impair the function of the urothelium because of
fibrosis and nerve changes in bladder tissue, leading to an
acute local inflammatory response and chronic lower
urinary tract symptoms (LUTS), whether or not associated
with gross haematuria and pain [6,7].
Several strategies have been used to treat radiation-
induced cystitis [3,8,9]. However, with the possible excep-
tion of modest effects with hyperbaric oxygen, most of these
treatments have failed to demonstrate optimal and long-
term efficacy [1,10]. In 2019, the International Consultation
on Incontinence Research Society identified gaps in the
knowledge on effects of radiation on the lower urinary tractand proposed several questions that remained to be
addressed through further research [11].
Several clinical studies have shown the efficacy of
intravesical instillation of high concentrations of sodium
hyaluronate and sodium CS in protecting the urothelium in
different settings [12–15]. Considering the positive results
obtained for intravesical HA and CS instillation for the
treatment of bladder diseases such as urinary tract
infections and bladder pain syndrome, which symptomati-
cally resemble radiation-induced cystitis, we reasoned that
protection of the urothelium by HA and CS during RT could
represent a preventive strategy capable of alleviating the
consequences, hence avoiding or improving the symptoms
of radiation-induced cystitis and improving QoL. Therefore,
we tested the hypothesis that intravesical HA/CS (iAluRil)
plus an oral formulation of HA, CS, curcumin, and quercetin
(iAluRil Soft Gels) may prevent acute and late radiation-
induced cystitis and improve quality of life.
2. Patients and methods
2.1. Study design
This was an investigator-initiated, European, unblinded, randomised
controlled trial (active vs no additional treatment) conducted in seven
centres in four countries (Italy, Slovakia, Spain, Turkey) in a selected
population of men with prostate cancer who underwent RT: the
Multicentre International Study for the Prevention with iAluRil of Radio-
induced Cystitis (MISTIC).
The study was approved by the medical research ethics board of each
participating centre and was conducted in compliance with the
International Conference on Harmonization/Good Clinical Practice
guidelines, national laws, applicable regulatory requirements, and the
ethical principles of the Declaration of Helsinki. Specifically, the study
was approved by the Ethics Committees of Universidad Autónoma de
Barcelona, Università Vita-Salute San Raffaele, Ospedali Careggi, the
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Fakultná nemocnica s poliklinikou Prešov, and Istanbul University. The
overall protocol is available on ClinicalTrial.gov (NCT03493997) and
follows the CONSORT guidelines.
2.2. Participants
Male patients aged 18 yr who were scheduled to undergo primary
intensity-modulated radiotherapy (IMRT) for localised prostate cancer
were enrolled. All patients provided written informed consent. The
participants did not enter the trial if any of the following applied: female;
life expectancy of <24 mo; radiologically confirmed metastasis;
documented urethral strictures; ongoing chemotherapy; previous
brachytherapy; history of chemoradiotherapy for prostate cancer;
previous treatment with bacillus Calmette-Guérin; postvoid residual
volume >200 ml; bladder calculi; neurogenic bladder; lower urinary
tract infection; unstable cardiovascular disease/congestive heart failure;
current nitrate or anticoagulant use; clinically significant hepatobiliary
or renal disease; history of significant central nervous system injuries
within 6 mo; and any other significant disease or disorder that, in the
opinion of the investigator, might either put the participant at risk
because of participation in the trial or influence the result of the trial or
the participant’s ability to participate in the trial.
2.3. Randomisation and masking
The randomisation (1:1) was carried out according to a predefined,
centre-specific randomisation list prepared using validated software
(Random Allocation Software version 1.0.0; https://doi.org/10.1186/
1471-2288-4-26) by the appointed personnel. Treatment was not
masked.
2.4. Procedures
All patients received external beam RT (EBRT) for prostate cancer,
delivered as IMRT using moderate hypofractionation with a simulta-
neous integrated boost, guided by fiducial intraprostatic markers
according to the European Organisation for Research and Treatment
of Cancer guidelines for primary prostate cancer RT, and lasting for 6 wk
[16]. After completion of screening (visit 1), eligible patients were
randomly assigned at a 1:1 ratio to receive either active treatment (group
A) or standard care (group B). Patients in group A received a sterile
solution containing sodium hyaluronate 1.6%, 800 mg/50 ml and sodium
chondroitin sulfate 2%, 1 g/50 ml (HA-SC; iAluRil Prefill; IBSA, Lodi, Italy)
via weekly intravesical instillation for 6 wk, plus an oral soft-gel
formulation (iAluRil Soft Gels; IBSA) containing 200 mg of CS, 20 mg of
HA, 200 mg of quercetin, and 100 mg of curcumin, one capsule twice a
day for 12 wk. Intravesical HA/SC was instilled in the 24 h before every RT
weekly session. Patients in group B did not receive any intravesical or oral
treatment. All other treatments were allowed except those mentioned in
the exclusion criteria.
Patients in both groups were followed up and assessed at 4 wk after
the first instillation (during the RT treatment period; visit 2); at 6 wk (at
the end of the RT period; visit 3); at 12 wk (6 wk after the end of RT; visit
4); and 1 yr after RT initiation (visit 5). During the planning of treatment,
regimen and average dose to the whole bladder was recorded to assess
the impact of EBRT on urinary symptoms.
2.5. Outcomes
The primary outcome was the absolute change from baseline to follow-
up in the Expanded Prostate Cancer Index Composite (EPIC) urinary
single and overall domain score, the International Consultation onIncontinence Questionnaire-Male Lower Urinary Tract Symptoms (ICIQ-
MLUTS) score, and the EuroQol Group EQ-5D-5L questionnaire score. The
secondary outcome was the rate of patients who stopped treatment with
intravesical or oral iAluRil because of intolerance or adverse events.
Tolerability endpoints included the discontinuation rate, significant
deviation from the study treatment protocol for Group A, and safety,
defined as drug-related adverse reactions.
2.6. Statistical analysis
To calculate the sample size, the EPIC questionnaire was fixed as the
reference and a power analysis was conducted to determine the number
of participants needed to detect an absolute change of 15 points in the
EPIC urinary domain total score between the first and last visit, given a
standard deviation of 20 and correlation of 0.500 between observations
for the same subject. A sample size of 21 subjects for each group achieved
80% power to detect this difference at a 0.05 significance level (PASS
version 11.0.7; NCSS, Kaysville, UT, USA). Data analyses for both efficacy
and safety outcomes were performed using an intention-to-treat (ITT)
approach; the ITT population was defined as all randomised patients.
The Shapiro-Wilk test was used to assess the variables followed a
normal distribution. The Mann-Whitney U test and Wilcoxon signed-
rank test were used for comparisons of independent and paired data,
respectively. Frequencies of qualitative variables were analysed using the
x2 test with Yates’ continuity correction or Fisher’s exact test.
Comparisons within and between groups over time were analysed
using a mixed-model repeated-measures analysis of variance (RM-
ANOVA), Mauchly’s test of sphericity, and Levene’s test for equality of
variances were used to exclude any possible violation of ANOVA
assumptions. Time (variable value at baseline and at each follow-up visit)
and group (therapy arms) were considered as within-subjects and
between-subject factors, respectively, with five time levels and two
group levels. Time  group interactions were also evaluated. All
statistical analysis was performed using SPSS version 26.0 (IBM Corp.,
Armonk, NY, USA). In all analyses, a two-sided p value <0.05 was
considered statistically significant.
3. Results
Of 57 patients screened between January 2017 and Decem-
ber 2019, seven did not agree to participate and one opted
for radical prostatectomy; finally, 49 were eligible for
inclusion. After completion of baseline assessments (visit
1), 25 patients were randomly assigned to group A and 24 to
the control group (group B; Fig. 1).
Patient demographics and disease characteristics were
similar in both groups (Table 1). The two groups were also
well balanced with regard to the RT received; there were no
significant differences in the number of sessions, RT doses,
or other RT parameters (Table 2).
Two patients in group B withdrew consent after
randomisation, and one in group B was diagnosed with a
new cancer and was ruled out. No patients withdrew from
the study because of catheter discomfort, and none
discontinued oral therapy because of side effects. All of
the patients were evaluated after 1 yr.
There were no significant differences in EPIC urinary
domain scores between the groups at baseline. When single
items were considered, scores at 12 mo for EPIC item 5
(p = 0.012) and item 7 (p = 0.033) were significantly higher
in group A than in group B. In group B, a significant
Fig. 1 – Flowchart of patient inclusion in the trial.
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up for item 1 (p = 0.021), item 6 (p = 0.005), and item 7
(p = 0.009). The subtotal scores for the two main categories
(urinary symptoms, items 1–5; and impact of symptoms on
QoL, items 6–7) and for the total score (items 1–7) were
significantly lower at 12 mo than at baseline in group B
(p = 0.05, p = 0.003, and p = 0.008, respectively). Changes in
QoL items from baseline to the 12 mo significantly differed
between groups A and B for item 6 (p = 0.002), item 7
(p = 0.016), the subtotal score for items 6–7 (p = 0.003), and
the overall score for items 1–7 (p = 0.006). All data are
reported in Table 3.
RM-ANOVA revealed statistically significant within-
group factors over time for all questionnaire sections and
a significant time  group interaction for the items 6–7
subscore and the total score (items 1–7), with lower values
in group B than in group A (Fig. 2).Table 1 – Baseline characteristicsa
Group A (n = 2
Median age, yr (IQR) 67 (64.5–75.5)
Median body mass index, kg/m2 (IQR) 26.1 (25.2–28.9
Median Charlson comorbidity index (IQR) 4 (4–4) 
Smokers, n (%) 6 (24) 
Positive DRE, n (%) 18 (72) 
Median PSA, ng/ml (IQR) 12.3 (7.7–24.3)
Median Gleason score (IQR) 7 (7–8) 
Median number of total cores, n (IQR) 12 (12–12) 
Median number of positive cores, n (IQR) 4 (3–8) 
Median percentage positive cores, % (IQR) 25 (17–71) 
DRE = digital rectal examination; IQR = interquartile range; PSA = prostate-specific
a Group A: intravesical sodium hyaluronate/sodium chondroitin sulfate plus oral
intravesical or oral treatment.There were no statistically significant differences at
baseline for overall ICIQ-MLUTS scores evaluating male
LUTS and impact on QoL (Table 4).
In group A, a statistically significant increase was observed
between baseline and last follow-up for the total score
(p = 0.019) and voiding symptom score (p = 0.007), while a
significant increase was observed for the total score
(p = 0.008), incontinence symptoms score (p = 0.004), and
bother score (p < 0.0001) in group B. Comparison of changes
in incontinence score and bother score from baseline to last
follow-up between the two groups revealed that the change
in score was significantly greater (worse condition) in group B
(p = 0.004 and p < 0.0001, respectively). RM-ANOVA showed
a statistically significant higher score over time for group B
versus A for total score (p < 0.0001), incontinence symptoms
score (p = 0.002), and bother score (p = 0.001). There was a
significant time  group interaction for the incontinence5) Group B (n = 24) p value
 71 (68.5–74.5) 0.508










 chondroitin sulphate, hyaluronic acid, quercetin, and curcumin. Group B: no
Table 2 – Radiotherapy treatment parameters
Group A (n = 25) Group B (n = 24) p value
Median number of sessions (interquartile range) 36 (29–36) 36 (30–37) 0.470
Median dose, Gy (interquartile range)
Prostate 72 (71–72) 72 (71–74) 0.432
Seminal vesicles 65 (56–65) 65 (65–67) 0.170
Lymph nodes 45 (45–49) 46 (45–48) 0.724
Bladder 44 (36–46) 44 (32–47) 0.941
Table 3 – Results for the urinary domain of the Expanded Prostate Cancer Index Compositea
Item Group A WG p value Group B WG p value BG p value MD BG (95% CI)
Visit 1 (baseline)
Number of patients 25 21
1. Over the past 4 weeks, how often have you leaked urine? 84  29.7 76.2  34.9 0.426
2. Over the past 4 weeks, how often have you urinated
blood?
100  0 100  0 1.000
3. Over the past 4 weeks, how often have you had pain or
burning with urination?
96  9.4 94 17.5 0.930
4. Which of the following best describes your urinary control
during the last 4 weeks?
77.5  20.9 79.5  26.8 0.516
5. How many pads or adult diapers per day did you usually
use to control leakage during the last 4 weeks?
96  14.7 88.9  26.5 0.266
Total for items 1–5 90.7  10.5 87.7  13.5 0.727
6. How big a problem, if any, has each of the following been
for you during the last 4 weeks?
79.7  15.8 82.7  16.4 0.431
7. Overall, how big a problem has your urinary function been
for you during the last 4 weeks?
77  19 76.2  20.1 0.981
Total for items 6–7 79.3  15.3 81.8  16.6 0.492
Total for items 1–7 84 11 84.3  13.5 0.604
Visit 5
Number of patients 23 21
1. Over the past 4 weeks, how often have you leaked urine? 77.2  30.1 64.3  37.6 0.247
2. Over the past 4 weeks, how often have you urinated
blood?
98.9  5.2 94 13.5 0.124
3. Over the past 4 weeks, how often have you had pain or
burning with urination?
96.7  8.6 86.9  23.2 0.46
4. Which of the following best describes your urinary control
during the last 4 weeks?
78.4 19 70  20.9 0.178
5. How many pads or adult diapers per day did you usually
use to control leakage during the last 4 weeks?
98.6  6.9 79.4  34.1 0.012
Total for items 1–5 90  7.7 78.9  20.7 0.096
6. How big a problem, if any, has each of the following been
for you during the last 4 weeks?
83.7  9.3 71.4  25.9 0.228
7. Overall, how big a problem has your urinary function been
for you during the last 4 weeks?
79.3  16.3 63.1  26.9 0.033
Total for items 6–7 83.1 9.1 70.2  25.7 0.157
Total for items 1–7 85.9  7.7 73.9  22.6 0.126
Change from baseline to visit 5
1. Over the past 4 weeks, how often have you leaked urine? 9.8  21 0.034 11.9  21.8 0.021 0.665 2.1 (10.9 to 15.1)
2. Over the past 4 weeks, how often have you urinated
blood?
1.1 5.2 0.317 6  13.5 0.059 0.124 4.9 (1.2 to 11)
3. Over the past 4 weeks, how often have you had pain or
burning with urination?
1.1 9.2 0.564 7.1  26.4 0.230 0.144 8.2 (3.6 to 20)
4. Which of the following best describes your urinary control
during the last 4 weeks?
1.4 15.7 0.655 9.5  23.9 0.150 0.107 8.1 (7.7 to 23.8)
5. How many pads or adult diapers per day did you usually
use to control leakage during the last 4 weeks?
0  0 1 9.5  23.9 0.084 0.070 9.5 (0.5 to 19.6)
Total for items 1–5 2.2  6.4 0.776 8.8  18.5 0.050 0.209 6.6 (1.7 to 14.8)
6. How big a problem, if any, has each of the following been
for you during the last 4 weeks?
2.2  10.9 0.138 11.3  15.8 0.005 0.002 13.5 (3.3–22.9)
7. Overall, how big a problem has your urinary function been
for you during the last 4 weeks?
0  13.1 1 13.1 18.7 0.009 0.016 13.1 (3.3–22.8)
Total for items 6–7 1.9  10.5 0.819 11.6  15.5 0.003 0.003 13.5 (5.4–21.4))
Total for items 1–7 0.1 7.1 0.592 10.4 16 0.008 0.006 10.5 (3.2–18)
BW = between groups; CI = confidence interval; MD = mean difference; WG = within-group.
a Score results are presented as mean  standard deviation.
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Fig. 2 – Repeated-measures analysis of variance for the urinary domain of the Expanded Prostate Cancer Index Composite (EPIC). Data are presented as
mean  standard deviation.
Table 4 – Results for the International Consultation on Incontinence Questionnaire-Male Lower Urinary Tract Symptoms
Group A WG p value Group B WG p value BG p value MD BG (95% CI)
Visit 1 (baseline)
Number of patients 25 21
Total score 15.6  5.7 15.1 7.6 0.921
Voiding symptoms score 5.9  4.3 6.6  4.3 0.542
Incontinence symptoms score 6.4  3.0 5.5  3.3 0.385
Bother score 16.6  13.9 16.1 16.4 0.635
Visit 5
Number of patients 24 21
Total score 17.9  6.5 20.4  8 0.202
Voiding symptoms score 7.6  4.7 7.4  4.3 0.982
Incontinence symptoms score 6.3  3.4 9.3  4.9 0.017
Bother score 13.5  9.5 27.4  24.6 0.099
Change from visit 1 to visit 5
Total score 2.3  3.8 0.019 5.2  7.9 0.008 0.391 2.9 (6.7 to 0.7)
Voiding symptoms score 1.7  3.1 0.007 0.8  4.1 0.270 0.280 0.9 (1.3 to 3)
Incontinence symptoms score 0.1  2.2 0.877 3.8  5.0 0.004 0.004 3.9 (6.1 to 1.6)
Bother score 1.6  6.7 0.19 11.3  15.4 <0.0001 <0.0001 12.9 (19.9 to 5.9)
BW = between groups; CI = confidence interval; MD = mean difference; WG = within-group.
aScore results are presented as mean  standard deviation.
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higher scores in group B than in A (Fig. 3).
There were no significant differences between the
groups in overall EQ-5D-5L scores at baseline. Group A
had a significantly higher score for the Health today item at
12 mo when compared to group B (p = 0.028). These data are
summarised in Table 5.
RM-ANOVA revealed a statistically significant within-
subjects factor over time (p = 0.039) and a significant time 
group interaction (p < 0.0001), with a higher score in group
A than in B for the Health today domain only (Fig. 4).
Intravesical treatment was very well tolerated, as
substantiated by full compliance for all patients, who
retained the intravesical solution in the bladder for at least
30 min without any distress. Overall, there were seven mild-
to-moderate (grade 1–2) drug-related adverse events,
including haematuria, nausea, and urticaria reported bythree patients. There were no serious (grade 3–4) drug-
related adverse events or treatment-related withdrawals.
4. Discussion
To the best of our knowledge, MISTIC is the first unblinded
randomised controlled trial (active treatment vs no
treatment in addition to RT) on the prevention of
radiation-induced cystitis assessing a broad range of
urinary symptoms and QoL using specific questionnaires.
Although new precision medicine RT modalities aim to
personalise RT based on individual radiosensitivity, the
number of patients affected by acute and late radiation
cystitis is still relatively high and remains a challenge for
health care systems [11]. Available options at present include
different drugs for acute cystitis (anti-inflammatory, anti-
biotics, analgesics, antimuscarinics), bladder irrigation (with
Fig. 3 – Repeated-measures analysis of variance for the International Consultation on Incontinence Questionnaire-(ICIQ) Male Lower Urinary Tract
Symptoms. Data are presented as mean  standard deviation.
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formalin, HA, and HA/CS), coagulation or selective embolisa-
tion of bleeding vessels, and hyperbaric oxygen therapy for
chronic conditions [3,9]. These modalities are not always
successful, and radical cystectomy is the only remaining
option for severe chronic intractable radiation cystitis.
Only a few studies have tried to investigate a preventive
strategy and timing of the intervention. Some have shown
that a shorter time from RT to treatment may positively
improve patient outcomes, supporting the need for early
treatment to alleviate or prevent urinary symptoms [17]. In
the current study, we started intravesical instillation andoral treatment concurrently with RT initiation and contin-
ued the oral treatment for 12 wk. The aim was to protect the
patient from acute radiation-induced bladder injuries and
to prevent a negative outcome over time by consolidating
the protection of the urothelium.
A limited number of single-centre, nonrandomised, and
underpowered studies assessed the use of intravesical HA/
SC for the treatment of radiation-induced cystitis, although
this treatment has been extensively investigated for
recurrent urinary tract infection and LUTS [18,19]. In a
study of 23 consecutive patients with symptomatic cystitis
after external RT for prostate cancer, Gacci et al [20]
Table 5 – Results for the EuroQol Group EQ-5D-5L questionnairea
Group A WG p value Group B WG p value BG p value MD BG (95% CI)
Visit 1 (baseline)
Number of patients 25 21
Index score 0.858  0.09 0.843  0.15 0.578
Health today score 74 13.6 77.6  11 0.510
Visit 5
Number of patients 24 21
Index score 0.857  0.1 0.802  0.16 0.177
Health today score 79.8  9.8 70  15.9 0.028
Change from visit 1 to visit 5
Index score 0.001 0.04 0.972 0.041 0.15 0.266 0.190 0.04 (0.02 to 0.1)
Health today score 4.8  8.1 0.05 7.6  13.1 0.021 0.002 12.4 (5.9–18.9)
BW = between groups; CI = confidence interval; MD = mean difference; WG = within-group.
a Score results are presented as mean  standard deviation.
Fig. 4 – Repeated-measures analysis of variance for the EuroQol Group EQ-5D-5L questionnaire. Data are presented as mean  standard deviation.
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quency on logistic regression analysis (Interstitial Cystitis
Symptoms Index Q3: r = 0.293, p = 0.011 and r = 0.970,
p < 0.001). In our series we considered urinary symptoms,
not only nocturia, as well as QoL, using specific tools to
investigate changes from baseline to 12 mo. The results for
all questionnaires showed an improvement in QoL and
symptoms in patients who received the active treatment
(group A).
In the current study we combined intravesical HA/CS, a
well-documented treatment for LUTS, with a similar oral
preparation containing HA/CS and two dietary supple-
ments. To the best of our knowledge, this is the first trial to
combine the two formulations. There is a rationale in theliterature for the use of dietary supplements to treat
radiation-induced urinary symptoms, but it is limited to a
number of single-centre and underpowered studies. It is
thought that dietary supplements can have an impact
on mild to moderately severe acute radiation-induced
cystitis. Products containing flavonoids, anthocyanins, and
proanthocyanidins with strong antioxidant and anti-
inflammatory characteristics may protect the urothelium
from free radical damage. Campbell et al [21] investigated
the effects of cranberry juice, which contains flavonoids,
and other antioxidant and anti-inflammatory agents on
acute radiation cystitis in patients with prostate cancer.
Unfortunately, they did not find any statistically significant
difference in cystitis severity between the group using
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Bonetta et al [22] reported a significant decrease in cystitis
symptoms among 370 prostate cancer patients taking
standardised cranberry capsules during RT for prostate
carcinoma. However, the study was not randomised and the
study design appeared to be poor. Hamilton and co-workers
[23] carried out a double-blind placebo-controlled, under-
powered pilot study in 41 prostate cancer patients who took
cranberry capsules (containing 72 mg of proanthocyani-
dins) or placebo during RT treatment and for 2 wk after
treatment completion. They observed a small but statisti-
cally significant decrease in the incidence of pain/burning
and nocturia and an improvement in urinary flow strength
[23]. These results were not confirmed in a recent large
multicentre, double-blind, randomised, placebo-controlled
clinical trial in which patients were instructed to take two
cranberry capsules every day during RT and for 2 wk after
treatment [24]. The severity of acute radiation cystitis was
investigated using the modified Radiation Therapy Oncolo-
gy Group grading system, the validated O’Leary Interstitial
Cystitis Symptom and Problem Scale, and the novel
Radiation-Induced Cystitis Assessment Scale. Contrary to
expectations, the study failed to show that cranberry
capsules were superior to placebo with respect to pain/
burning, nocturia, and strength of urinary flow.
Curcumin, the main natural polyphenol found in the
rhizome of Curcuma longa, has a benefit in inflammatory
conditions because of its antioxidant effects [25]. Combina-
tion with quercetin, a flavonoid found in fruits and
vegetables that has unique anti-inflammatory properties,
improves the intestinal absorption and bioavailability of
curcumin [26,27]. In addition, experimental evidence
suggests that the combination has a role as a potential
radioprotective factor [28]. Saadipoor et al [29] conducted a
randomised, double-blind, placebo-controlled phase 2 trial
of nanocurcumin in prostate cancer patients undergoing RT.
Sixty-four patients with prostate cancer were randomised
to receive oral nanocurcumin (120 mg/d) or placebo 3 d
before and during the course of RT. No significant between-
group difference in radiation-induced cystitis was observed.
Fersino et al [30] performed a randomised controlled trial in
40 patients who were randomised (1:1) to receive RT alone
or RT combined with iAluRil Soft Gels. The authors used the
International Prostate Symptom Score (IPSS) questionnaire
to investigate clinical outcomes. Although the IPSS is not
designed to capture the specific study population, iAluRil
Soft Gels appeared to have a beneficial role in reducing
genitourinary toxicity. In our study, we used a combination
of intravesical HA/CS and an oral preparation containing HA,
CS, curcumin, and quercetin, and assessed outcomes using a
specific questionnaire for the study cohort (ie, EPIC). The
concordance between the three different questionnaires
and the randomised study design support a high level of
evidence from our findings.
The study has some limitations. The lack of a placebo
and/or sham strategy group is the major drawback of
the present RCT. Unfortunately, choice of the dose and
duration for oral treatment was purely empirical.
Although the intravesical schedule was modulated inaccordance with previous experience with intravesical
HA/CS for the treatment of urinary tract infections or
painful bladder syndrome, no evidence-based schedule
exists for the dietary supplement. No data are reported on
the use of medical treatment for LUTS (eg, anticholiner-
gics, analgesics, hyperbaric oxygen) or the number of
readmissions for lower urinary tract complications (eg,
haematuria). Furthermore, many patients who undergo
pelvic RT also have symptoms from adjacent organs, such
as the rectum and genitalia. We did not investigate these
scenarios in our series and we recognise the need for
future studies to address these important aspects. The
non-negligible rate of patients presenting with pre-
existing LUTS related to benign prostate hyperplasia in
our series might represent a confounding bias. However,
this potential bias is balanced by the randomisation.
Finally, our observations stopped after 1 yr and we have no
long-term follow-up data.
5. Conclusions
In conclusion, our study shows a beneficial effect of
intravesical HA-SC plus the oral combination of curcumin,
quercetin, HA, and CS for prevention of acute and radiation-
induced cystitis. Although the improvement in symptoms
was maintained after 1 yr, our findings do not allow any
conclusions regarding the intermediate- and long-term
effects of oral and intravesical preparations on the risk of
late radiation-induced cystitis.
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